Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications
Authors:
- Paschalis KarakasisPKPaschalis Karakasis
- Panagiotis TheofilisPTPanagiotis Theofilis
- Panayotis K. VlachakisPVPanayotis K. Vlachakis
- Nikias MilarasNMNikias Milaras
- Kallirhoe KalinderiKallirhoe Kalinderi
- Dimitrios PatouliasDPDimitrios Patoulias
- Antonios P. AntoniadisAAAntonios P. Antoniadis
- Nikolaos FragakisNikolaos Fragakis
Open Access
- 30 July 2025
- journal article
- review article
- Published by MDPI AG in Medical Sciences
- Vol. 13 (3) , 102
Abstract
Cardiac arrhythmias remain a major source of morbidity and mortality, often stemming from molecular and structural abnormalities that are insufficiently addressed by current pharmacologic and interventional therapies. Gene therapy has emerged as a transformative approach, offering precise and durable interventions that directly target the arrhythmogenic substrate. Across the spectrum of inherited and acquired arrhythmias—including long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, atrial fibrillation, and post-infarction ventricular tachycardia—gene-based strategies such as allele-specific silencing, gene replacement, CRISPR-mediated editing, and suppression-and-replacement constructs are showing growing translational potential. Advances in delivery platforms, including cardiotropic viral vectors, lipid nanoparticle-encapsulated mRNA, and non-viral reprogramming tools, have further enhanced the specificity and safety of these approaches. Additionally, innovative applications such as biological pacemaker development and mutation-agnostic therapies underscore the versatility of genetic modulation. Nonetheless, significant challenges remain, including vector tropism, immune responses, payload limitations, and the translational gap between preclinical models and human electrophysiology. Integration of patient-derived cardiomyocytes, computational simulations, and large-animal studies is expected to accelerate clinical translation. This review provides a comprehensive synthesis of the mechanistic rationale, therapeutic strategies, delivery platforms, and translational frontiers of gene therapy for cardiac arrhythmias.Keywords
This publication has 154 references indexed in Scilit:
- Cardiomyopathy-Associated Gene Variants in Atrial FibrillationJAMA Cardiology, 2025
- Ventricular arrhythmias in acute myocardial ischaemia—Focus on the ageing and sexAgeing Research Reviews, 2022
- Engineered Cardiac Pacemaker Nodes Created by TBX18 Gene Transfer Overcome Source–Sink MismatchAdvanced Science, 2019
- Design of AAV Vectors for Delivery of Large or Multiple Transgenes2019
- German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia managementClinical Research in Cardiology, 2018
- Pharmacogenetics of Drug-Induced QT Interval Prolongation: An UpdateDrug Safety, 2015
- Gene delivery methods in cardiac gene therapyThe Journal of Gene Medicine, 2011
- Cell Therapy for Cardiovascular Disease: A Comparison of Methods of DeliveryJournal of Cardiovascular Translational Research, 2010
- So Little Source, So Much Sink: Requirements for Afterdepolarizations to Propagate in TissueBiophysical Journal, 2010
- Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesisCardiovascular Research, 2005